Brief: Poseida Therapeutics Announces FDA Orphan Drug Designation Granted To P-Bcma-Allo1 For The Treatment Of Multiple Myeloma

Poseida Therapeutics

13/03/2024 20:38

Poseida Therapeutics Inc  PSTX.O :
    * POSEIDA THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION
GRANTED TO P-BCMA-ALLO1 FOR THE TREATMENT OF MULTIPLE MYELOMA
    * POSEIDA THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION
GRANTED TO P-BCMA-ALLO1 FOR THE TREATMENT OF MULTIPLE MYELOMA
    * POSEIDA THERAPEUTICS INC - LOOK FORWARD TO CONTINUING OUR
WORK
ON PHASE 1 STUDY OF P-BCMA-ALLO1 AND PLAN TO SHARE FURTHER
CLINICAL UPDATES IN 2024
    * POSEIDA THERAPEUTICS INC - PLANS TO PROVIDE AN ADDITIONAL
CLINICAL UPDATE ON P-BCMA-ALLO1 PROGRAM AT A SCIENTIFIC MEETING
IN SECOND HALF OF 2024

Source text for Eikon:  ID:nPn1jm7M9a 
Further company coverage:  PSTX.O